{"id":"placebo-matching-fingolimod","safety":{"commonSideEffects":[{"rate":"25-30","effect":"Headache"},{"rate":"10-15","effect":"Liver enzyme elevation"},{"rate":"5-10","effect":"Bradycardia (on initiation)"},{"rate":"0.4-0.8","effect":"Macular edema"},{"rate":"20-30","effect":"Infections"},{"rate":"10-15","effect":"Hypertension"}]},"_chembl":{"chemblId":"CHEMBL314854","moleculeType":"Small molecule","molecularWeight":"307.48"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fingolimod binds to sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5) on lymphocytes and vascular endothelial cells. This binding causes internalization and degradation of the S1P1 receptor, preventing lymphocyte exit from secondary lymphoid organs and reducing their migration to inflamed tissues in the CNS. This mechanism reduces the autoimmune attack on myelin in multiple sclerosis.","oneSentence":"Fingolimod is a sphingosine-1-phosphate receptor modulator that reduces lymphocyte egress from lymphoid tissues, decreasing their infiltration into the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:56.346Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis"},{"name":"Secondary progressive multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT07483632","phase":"PHASE3","title":"A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)","status":"NOT_YET_RECRUITING","sponsor":"Biogen","startDate":"2026-11-16","conditions":"Relapsing Forms of Multiple Sclerosis","enrollment":185},{"nctId":"NCT04926818","phase":"PHASE3","title":"Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-10-05","conditions":"Multiple Sclerosis (MS)","enrollment":129},{"nctId":"NCT05123703","phase":"PHASE3","title":"A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-05-19","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":188},{"nctId":"NCT01892722","phase":"PHASE3","title":"Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2013-07-26","conditions":"Multiple Sclerosis","enrollment":240},{"nctId":"NCT01625182","phase":"PHASE3","title":"Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12-22","conditions":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy","enrollment":106},{"nctId":"NCT00731692","phase":"PHASE3","title":"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-07-28","conditions":"Primary Progressive Multiple Sclerosis","enrollment":970},{"nctId":"NCT01941004","phase":"PHASE3","title":"Safety and Efficacy of Fingolimod in MS Patients in China","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2014-06","conditions":"Multiple Sclerosis (Relapsing Remitting)","enrollment":""},{"nctId":"NCT02141022","phase":"NA","title":"Computerized Exercise Training for Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya","status":"COMPLETED","sponsor":"Stony Brook University","startDate":"2013-08","conditions":"Multiple Sclerosis, Cognitive Deficits, Gilenya Modifying Therapy for MS","enrollment":20},{"nctId":"NCT01499667","phase":"PHASE3","title":"Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-09","conditions":"Relapsing Remitting Multiple Sclerosis (RRMS)","enrollment":142},{"nctId":"NCT00355134","phase":"PHASE3","title":"Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-06","conditions":"Multiple Sclerosis","enrollment":1083},{"nctId":"NCT01199861","phase":"PHASE3","title":"Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-08","conditions":"Relapsing Multiple Sclerosis","enrollment":138}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo matching fingolimod","genericName":"Placebo matching fingolimod","companyName":"Biogen","companyId":"biogen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fingolimod is a sphingosine-1-phosphate receptor modulator that reduces lymphocyte egress from lymphoid tissues, decreasing their infiltration into the central nervous system. Used for Relapsing-remitting multiple sclerosis, Secondary progressive multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}